Stockholders' Equity and Common Stock Purchase Warrants (Details Narrative)

v3.19.1

Stockholders' Equity and Common Stock Purchase Warrants (Details Narrative) - USD ($)																	1 Months Ended								12 Months Ended
	Dec. 27, 2018	Aug. 22, 2018	Jul. 31, 2018	Jun. 12, 2018	Jun. 01, 2018	May 12, 2018	Apr. 05, 2018	Mar. 15, 2018	Feb. 08, 2018	Jan. 25, 2018	Jan. 23, 2018	Jan. 19, 2018	Jan. 11, 2018	Nov. 17, 2017	Apr. 28, 2017	Apr. 28, 2016	Mar. 31, 2018	Jan. 31, 2018	Dec. 31, 2017	Dec. 30, 2017	Nov. 30, 2017	Oct. 31, 2017	Sep. 30, 2017	Mar. 31, 2017	Dec. 31, 2018	Dec. 31, 2017	Sep. 30, 2018	Apr. 04, 2018	Jul. 31, 2017	Jul. 03, 2017	Dec. 31, 2016
Common stock, shares authorized																			75,000,000						75,000,000	75,000,000
Common stock, par value per share																			$ 0.001						$ 0.001	$ 0.001
Common stock, shares issued																			14,551,234						27,142,979	14,551,234
Common stock, shares outstanding																			14,551,234						27,142,979	14,551,234
Number of common stock value issued																									$ 4,274,661
Additional paid-in capital																			$ 14,012,053						32,619,282	$ 14,012,053
Gross proceeds from issuance initial public offering																									$ 4,388,099
Exercise price per share																									$ 5.00
Modification of the Series Z warrant agreement																									$ (1,140,995)
Calculated aggregate estimated fair value																									96,480	(1,942,501)
Stock-based compensation expense																									$ 1,228,699	$ 1,048,127
Three Individual Physician Inventors [Member]
Number of shares issued						289,679
Parent Company [Member]
Number of shares issued						8,187,499
Unit Purchase Option [Member] | IPO [Member]
Number of shares issued		53,000
Dawson James Securities, Inc., [Member] | Underwriting Agreement [Member]
Common stock, shares issued												362,292
Number of shares issued										234,540	2,415,278	2,415,278
Shares issued price per share												$ 1.80
Underwriter's discount										$ 4,388,099
Gross proceeds from issuance initial public offering										$ 113,438
Underlying unit												$ 1.80
Lucid Diagnostics Inc [Member]
Common stock, shares issued																									10,000,000
Common stock, shares outstanding																									10,000,000
Majority ownership interest percentage																									81.875%
Lucid Diagnostics Inc [Member] | 2014 Stock Plan to Non-employees [Member]
Stock-based compensation expense																									$ 12,485
Lucid Diagnostics Inc [Member] | 2018 Stock Plan to Non-employees [Member]
Stock-based compensation expense																									$ 40,748
Lucid Diagnostics Inc [Member] | Share Subscription Agreement [Member]
Number of shares issued						10,000,000
Shares issued price per share						$ 0.001
Case Western Reserve University [Member]
Number of shares issued						943,464
Equity Subscription Rights Offering [Member]
Number of shares issued				9,000,000
Equity subscription period date				Jun. 07, 2018
Equity subscription purchases description				The equity subscription provided for the purchase of a common stock unit at a $1.15 per unit, with each such unit comprised of one share of common stock of the Company and one Series Z Warrant, and immediately separated upon issue into its underlying components.
Gross proceeds from issuance of common stock				$ 10,400,000
Commissions and fees				1,000,000
Series Z Warrants [Member]
Number of shares issued		437,031																							20,000
Additional paid-in capital				$ 2,100,000
Exercise price per share							$ 3.00																		$ 3.00
Convertible preferred stock, shares issued upon conversion					1.60
Number of warrants issued		53,000						1,399,185																	16,815,039
Warrant issued and outstanding																									16,815,039
Warrant maturity date																									Apr. 30, 2024
Warrant exercise price description																									Upon issue, a Series Z Warrant is exercisable to purchase one share of common stock of the Company at an exercise price of $1.60 per share, effective June 1, 2018. The Series Z Warrant exercise price was initially $3.00 per share through May 31, 2018. On May 15, 2018, the Company's board of directors approved a reduction to the Series Z Warrant exercise price to $1.60 per share, effective June 1, 2018, upon completion of the period-of-notice to the holders of Series Z Warrants then issued and outstanding. See herein below for further information with respect to the modification expense recognized in connection with the Series Z Warrant exercise price adjustment. The Series Z Warrant $1.60 exercise price is not subject-to further adjustment, unless by action of the PAVmed Inc board of directors, or the effect of stock dividends, stock splits or similar events affecting the common stock of the Company.
Redemption price per share for outstanding warrants																									$ 0.01
Weighted average closing price of common stock																									9.00
Modification of the Series Z warrant agreement					$ 1,140,995
Calculated aggregate estimated fair value		$ 1,060					$ 3,304,377
Underlying unit							$ 1.66
Expected volatility							55.00%
Risk free rate							2.70%
Expected term (years)							2 years 8 months 12 days
Dividend yield							0.00%
Series Z Warrants [Member] | IPO [Member]
Number of shares issued		4,638,818
Series Z Warrants [Member] | Minimum [Member]
Exercise price per share					$ 1.60
Series Z Warrants [Member] | Maximum [Member]
Exercise price per share					$ 3.00
Series Z Warrants [Member] | Series A and Series A -1 Exchange Offer March 15,2018 Exchange Date [Member]
Number of warrants issued								2,739,190
Series Z Warrants [Member] | Series W Warrants Offer-to-Exchange [Member]
Number of warrants issued							5,075,849
Warrant modification expense							$ 766,456
Calculated aggregate estimated fair value							$ 3,304,377
Series Z Warrants [Member] | Equity Subscription Rights Offering [Member]
Number of warrants issued				9,000,000
Series Z Warrants [Member] | UPO Offer-to-Exchange [Member]
Number of warrants issued		53,000
Calculated aggregate estimated fair value		$ 3,180
Underwritten Public Offering [Member]
Number of shares issued																		2,649,818
Series W Warrants [Member]
Number of shares issued		124,042
Gross proceeds from issuance initial public offering									$ 50,520
Number of warrant exercised									34,345
Exercise price per share									$ 2.00				$ 2.00						$ 5.00						$ 5.00	$ 5.00
Proceeds from warrant exercises									$ 68,690										$ 59,250					$ 2,000
Number of warrants issued							10,151,682												10,567,845						381,818	10,567,845
Warrant issued and outstanding																			10,567,845						381,818	10,567,845
Warrant exercisable date																									Oct. 28, 2016	Oct. 28, 2016
Warrant expiry date													Feb. 08, 2018												Jan. 29, 2022	Jan. 29, 2022
Calculated aggregate estimated fair value							$ 2,537,921
Expected volatility							55.00%
Risk free rate							2.50%
Expected term (years)							3 years 9 months 18 days
Dividend yield							0.00%
Series W Warrants [Member] | IPO [Member]
Number of shares issued		257,776													20,000
Number of warrants issued																1,060,000
Redemption price per share for outstanding warrants															$ 0.01
Weighted average closing price of common stock															$ 10.00
Unexercised warrants																9,560,295
Series W Warrants [Member] | Unit Purchase Options [Member]
Exercise price per share		$ 1.60
Common Stock [Member]
Common stock, shares outstanding																			14,551,234						27,142,979	14,551,234					13,330,811
Number of shares issued																	274,257				122,080	532,000	11,850	400	2,649,818
Number of common stock value issued																									$ 2,650
Conversion of stock, shares converted																										22,093
Series S Warrants [Member]
Common stock, par value per share																														$ 4.50
Number of shares issued		2,659,720
Number of warrant exercised																					122,080
Exercise price per share																														$ 0.01
Proceeds from warrant exercises																	$ 2,743				$ 5,320	$ 5,320
Number of warrants issued																			1,473,640						1,199,383	1,473,640
Warrant issued and outstanding																			1,473,640						1,199,383	1,473,640
Warrant maturity date																									Jun. 30, 2032
Warrants exercised on cashless basis																					122,360
Proceeds from senior secured note																									$ 3,434,452
Series S Warrants [Member] | Note and Security Purchase Agreement [Member]
Exercise price per share																									$ 0.01
Number of warrants issued																									2,660,000				2,660,000
Series B Convertible Preferred Stock [Member]
Number of shares issued								476,234
Number of common stock value issued
Convertible preferred stock, shares issued upon conversion			33,325					499,334
Conversion of stock, shares converted			33,325
Common Stock 1 [Member]
Number of shares issued																					532,000
Series S Warrants [Member]
Number of warrant exercised																					1,064,000	532,000
Proceeds from warrant exercises																					$ 10,640	$ 10,640
Series A-1 Warrants [Member]
Exercise price per share																									$ 6.67
Conversion of stock, shares converted														154,837					154,837
Number of warrants issued								279,837											279,837						0	279,837
Warrant issued and outstanding																			279,837						0	279,837
Warrant maturity date																									Apr. 30, 2024
Warrant modification expense																									$ 222,000
Calculated aggregate estimated fair value																									$ 310,450
Warrants expiration date																									As discussed in Note 13, Preferred Stock, the Series A-1 Warrant Agreement Amendment No.1 provided for a Series A-1 Warrant to be exchanged for four Series X-1 Warrants, or additionally, exchanged for five Series W Warrants. The Series X-1 Warrants replaced the previous election to exchange one Series A-1 Warrant for four Series X Warrants. Notwithstanding, the Series X-1 Warrants are substantively equivalent to the Series X Warrants with respect to material contractual terms and conditions, including the same $6.00 per share exercise price, and dates of exercisability and expiry.
Series A-1 Warrants [Member] | Series A -1 Preferred Stock Units Private Placement [Member]
Number of warrants issued																												125,000
Series A Warrants [Member]
Exercise price per share																									$ 6.61
Conversion of stock, shares converted								268,001						154,837					154,837
Number of warrants issued																			268,001							268,001	0
Warrant issued and outstanding																			268,001							268,001	0
Redemption price per share for outstanding warrants																									$ 8.00
Calculated aggregate estimated fair value								$ (246,561)																	$ (246,561)	$ (1,942,501)
Warrants expiration date																									Additionally, through April 30, 2024, each Series A Warrant, at the election of the holder, could be exchanged for four Series X Warrants, with such warrants exercisable for one share of common stock of the Company at $6.00 per share, with such exercise price not subject to further adjustment, except in the event of stock dividends, stock splits or similar events affecting the common stock of the Company. The Series X Warrants were exercisable commencing on the first trading day following October 31, 2018 and would have expired April 30, 2024.
Series A Warrants [Member] | Series A Preferred Stock Private Placement [Member]
Number of warrants issued																								422,838
Series X Warrants [Member]
Exercise price per share																									$ 6.00
Series Z Warrants One [Member]
Number of warrants issued								1,340,005
Unit Purchase Options [Member]
Exercise price per share		$ 5.50														$ 5.50
Number of warrants issued		53,000
Warrant issued and outstanding		53,000
Modification of the Series Z warrant agreement		$ 2,120
Warrant expiry date		Jan. 29, 2021
Number of common stock and warrant offered in one unit		53,000														53,000
Fair value assumptions amount																$ 105,100
Underlying unit																$ 5.00
Expected volatility																50.00%
Risk free rate																1.28%
Expected term (years)																4 years 7 months 6 days
Dividend yield																0.00%
Unit Purchase Options One [Member]
Exercise price per share																$ 5.00
Series A Warrants and Series A-1 Warrants [Member]
Number of shares issued		2,739,190
Noncontrolling Interest [Member]
Number of common stock value issued
Noncontrolling Interest [Member] | Lucid Diagnostics Inc [Member]
Majority ownership interest percentage																									18.125%
Equity Subscription Rights Offering [Member]
Common stock, par value per share				$ 7.1
Common stock, shares issued				17,509,654
Common stock, shares outstanding				17,509,654
Maximum equity subscriptions paid				9,000,000
Purchase of common stock unit price per share				$ 1.15
Subscriptions offering costs				$ 200,000
Series A Convertible Preferred Stock
Convertible preferred stock, shares issued upon conversion																			12,072		10,021					12,072
Conversion of stock, shares converted																				10,000	8,334
Senior Secured Note [Member]
Number of shares issued	600,000
Proceeds from senior secured note																									$ 1,408,125
Senior Convertible Note [Member]
Convertible preferred stock, shares issued upon conversion																									50,044